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summary
Activation of AMP-activated protein kinase (AMPK) results 
in glucose transporter 4 (GLUT4) translocation from the 
cytosol to the cell membrane, and glucose uptake in the 
skeletal muscles. This increased activation of AMPK can be 
stimulated by a pharmacological agent, AICAR (5′-aminoim-
idazole-4-carboxamide ribonucleoside), which is converted 
intracellularly into ZMP (5′-aminoimidazole-4-carboxamide-
ribonucleosidephosphate), an AMP analogue. We utilised 
AICAR and ZMP to study GLUT4 translocation and glucose 
uptake in isolated cardiomyocytes. 
Adult ventricular cardiomyocytes were treated with 
AICAR or ZMP, and glucose uptake was measured via 
[3H]-2-deoxyglucose accumulation. PKB/Akt, AMPK and 
acetyl-CoA-carboxylase phosphorylation and GLUT4 trans-
location were detected by Western blotting or flow cytom-
etry.
AICAR and ZMP promoted AMPK phosphorylation. 
Neither drug increased glucose uptake but on the contrary, 
inhibited basal glucose uptake, although GLUT4 transloca-
tion from the cytosol to the membrane occurred. Using flow 
cytometry to detect the exofacial loop of the GLUT4 protein, 
we showed ineffective insertion in the membrane under these 
conditions. Supplementing with nitric oxide improved inser-
tion in the membrane but not glucose uptake. 
We concluded that activation of AMPK via AICAR or 
ZMP was not sufficient to induce GLUT4-mediated glucose 
uptake in isolated cardiomyocytes. Nitric oxide plays a role 
in proper insertion of the protein in the membrane but not 
in glucose uptake. 
Keywords: AMPK, AICAR, GLUT4, GLUT4 exofacial loop, 
cardiomyocytes
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AMP-activated protein kinase (AMPK) plays a key role in 
maintaining energy homeostasis in the cell1 by recognising ATP 
depletion,2 initiating changes to restore cellular ATP levels and 
inhibiting ATP-utilising anabolic pathways.3 In heart and skeletal 
muscle, AMPK plays an important role in accelerating fatty acid 
oxidation, FAT/CD36 translocation and fatty acid uptake, as well 
as glut4 translocation, glucose uptake and glycolysis.4,5 AMPK 
is activated by cellular stress, which alters the AMP:ATP ratio 
– this can be nutrient stress, lack of oxygen or exercise-induced 
stress.4,6
The AMPK signalling pathway provides an alternative to the 
insulin-dependant glucose uptake pathway in muscle. Insulin-
stimulated activation of glut4 translocation via activation of 
phosphatidyl-inositol-3 kinase (PI3-K) and PKB/Akt has been 
extensively researched. Resistance of muscle to the effects of 
insulin is a hallmark of pre-diabetes. This reduction in insulin 
sensitivity is reflected in decreased insulin-stimulated glucose 
uptake.7 Since AMPK activates glucose uptake via a distinctly 
different signalling pathway than insulin, it may present a 
mechanism to manipulate pharmacologically to treat this disease. 
Indeed, in insulin-resistant humans and rodents, regular exer-
cise, known to activate AMPK, enhances insulin sensitivity.8-12 
Repeated activation of AMPK may therefore be a mechanism to 
improve insulin sensitivity.13
Furthermore, it was demonstrated that activation of AMPK is 
responsible for glucose uptake by hearts subjected to ischaemia, 
underscoring the importance of this kinase in the pathophysiol-
ogy of the heart.14 AICAR (5′-aminoimidazole-4-carboxamide 
ribonucleoside) is an adenosine analogue which is taken up into 
the cells and converted to the monophosphorylated nucleotide, 
ZMP (5′-aminoimidazole-4-carboxamide-ribonucleosidephos-
phate), by adenosine kinase.6,15 It was described as a specific acti-
vator of AMPK16 in intact cells. In has also been found that ZMP, 
an analogue of AMP, mimics the effects of AMP on allosteric 
activation of AMPK,17 and the promotion of phosphorylation 
and activation of AMPK by the AMPK kinase, LKB118 without 
changing the ATP:ADP or ATP:AMP ratio in the cell.16 
There are numerous studies showing that AICAR increases 
AMPK phosphorylation as well as glucose uptake in skeletal 
muscle, the latter mediated via GLUT4 translocation.19-21 There 
are, however, only a few studies to date showing effects of 
AICAR on glucose uptake in the heart, some utilising papillary 
muscle,14 whereas Jing and Holman used oligomycin to activate 
AMPK in cardiomyocytes.22
GLUT4 protein in the heart is largely confined to an intracel-
lular vesicle storage site in the basal, non-stimulated state.23,24 It 
becomes recruited to the cell surface under the influence of insu-
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lin25-27 or stimuli such as contraction or hypoxia. GLUT4 vesicles 
respond to insulin in a marked and dramatic way, increasing 
GLUT4 levels in the membrane up to nine times that of basal 
levels.28 The protein is recycled via endocytosis in clathrin-
coated vesicles.29
It has, however, been recognised that translocation of GLUT4 
to the membrane, and glucose uptake by the GLUT4 transport-
ers are not always reconcilable. There is a marked discrepancy 
between glucose uptake and translocation of GLUT4.30 Although 
our understanding of the regulation of GLUT4 translocation 
from the intracellular to the membrane compartments has 
expanded rapidly over the past years,31 the exact mechanisms 
governing these events, especially at the site of fusion with 
the cell membrane, is not fully understood. Events elicited by 
stimulation with insulin have been the focus of intense research, 
whereas less is known of those elicited by AMPK activation. 
However, stimulation with activators of AMPK share some of the 
downstream signalling events of the insulin pathway.32,33 
We used isolated, adult ventricular myocytes stimulated with 
AICAR and ZMP to correlate glucose uptake and GLUT4 trans-
location after AMPK activation. The results demonstrated that in 
cardiomyocytes, activation of AMPK was not sufficient to affect 




AICAR, ZMP, insulin and Triton X-100 were obtained from 
Sigma, type 2 collagenase was from Worthington, bovine 
serum albumin (BSA) fraction V, fatty acid-free from Roche 
Diagnostics and 2-deoxy-D-[3H]glucose from New England 
Nuclear. The ECL Western blotting detection reagents, anti-
rabbit Ig, horseradish peroxidase-linked whole secondary anti-
body were from Amersham Biosciences, UK Ltd, GLUT4 
(H-61): sc-7938 rabbit polyclonal antibody was from Santa 
Cruz Biotechnology Inc., phospho-PKB/Akt (Ser473), phospho-
AMPK-α (Thr172) and Phospho-ACC antibodies were from Cell 
Signalling technology. The anti-GLUT4 (exofacial loop) was 
purchased from Chemicon International (Temecula, California, 
USA), and Zenon Alexa Fluor 488 Rabbit IgG Labeling Kit 
was acquired from Molecular Probes (Eugene, Oregon, USA). 
Paraformaldehyde was purchased from Merck (Cape Town, 
RSA) and Dulbecco’s phosphate-buffered saline (PBS) from 
Gibco (Grand Island, New York, USA).
Animals
Male Wistar rats weighing between 250 and 300 g were used in 
all experiments. Animals were bred and kept in the AAALAC-
accredited facility of this institution. The project was approved 
by the Ethics committee of the Faculty of Health Sciences, 
University of Stellenbosch and conformed to the Guide for the 
Care and Use of Laboratory Animals of the NIH (Publication 
No. 85-23, revised 1996). Animals were anaesthetised with 
sodium pentobarbital (160 mg/kg) before experimentation. 
Preparation of cardiomyocytes 
Rod-shaped ventricular cardiomyocytes were obtained by colla-
genase perfusion, essentially as described previously.34 Isolated 
cells were filtered through a nylon mesh (200 × 200 µm) and 
gently spun down (3 min, 100 rpm). The resulting pellet was 
resuspended in HEPES buffer (10 mM HEPES pH 7.4, 6 mM 
KCl, 1 mM Na2HPO4, 0.2 mM NaH2PO4, 1.4 mM MgSO4, 128 
mM NaCl, 5.5 mM glucose, 2 mM pyruvate, containing 1.25 
mM CaCl2, 2% BSA (fraction V, fatty acid free) and the cells 
were allowed to recover for 60 min on a slowly rotating plat-
form. Osmotic fragility coupled to trypan blue exclusion (TBE) 
and cell morphology were used as indices for assessment of cell 
viability.35 Viable cells varied between 70 and 80% and all cell 
isolates of less than 70% viability were discarded. At the end 
of experimentation, the viability of cell preparations was deter-
mined with propidium iodide. 
Propidium iodide staining
Propidium iodide (PI) staining was used to assess cell membrane 
permeability. Nuclear staining by PI was assessed with flow 
cytometric (FACS) analysis. Cardiac myocytes were incubated 
with 10 µM PI for 15 min before analysis. Data are expressed 
as mean fluorescence intensity as a percentage of control. FACS 
analysis was done with a FACSCalibur using Cellquest 3.3 soft-
ware (Becton Dickinson, San Jose, California, USA).
Detection of glucose uptake
Myocyte uptake of 2-deoxy-D-[3H] glucose (2DG) was meas-
ured as described previously.34 Cardiomyocytes (approximately 
0.5 mg protein) were placed in a total volume of 750 µl assay 
medium containing (in mmol/l): KCl 6, Na2HPO4 1, NaH2PO4 
0.2, MgSO4 1.4, NaCl 128, HEPES 10, CaCl2 1.25 plus 2% 
BSA (fraction V, fatty acid free) pH 7.4, 37°C, equilibrated with 
oxygen. Cells were equilibrated for 15 min in a shaking water 
bath (180 strokes/min) with or without phloretin (400 µM) for 
measurement of non-carrier-mediated glucose uptake. They were 
stimulated with or without insulin (15 min × 100 nM), AICAR 
(30 min × 1 mM) or ZMP (30 min × 1 mM) as indicated. Glucose 
uptake was initiated by the addition of 2-deoxy-D-[3H] glucose 
(1.5 µCi/ml; final 2-deoxy-D-glucose concentration 1.8 µM) and 
allowed to progress for 30 min before the reaction was stopped 
with phloretin (final concentration 400 µM). The cells were then 
centrifuged and the pellet was washed twice with HEPES buffer 
and dissolved in 1 ml 0.5 N NaOH. An aliquot of this solution 
was then used to assay protein concentration by the method of 
Lowry,36 and the rest was counted for radioactivity. 
Preparation of lysates for Western blotting
Cardiomyocytes were removed after stimulation with insulin, 
AICAR or ZMP as described above and placed on ice. The cells 
were centrifuged and washed three times with ice-cold HEPES 
buffer without albumin and lysed in 100 µl of lysis buffer (25 
mM HEPES, 50 mM β-glycerophosphate, 1 mM EGTA, 1% 
Triton X-100, 10 mM p-nitrophenyl phosphate, 1 mM Na3VO4, 
2.5 mM MgCl2, 10 µg/ml aprotonin, 10 µg/ml leupeptin, 1 mM 
phenylmethylsulphonyl fluoride and 1 mM 1-4-dithiothreitol, 
pH 7.4). The lysates were centrifuged at 15 000 × g for 10 min 
and the supernatants diluted with Laemmli sample buffer for 
SDS-PAGE. An aliquot of the supernatant was used for protein 
determination.37
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or two-way ANOVA followed by a Bonferroni correction or with 
the Students t-test where applicable, using GraphPad Prism 5; p 
< 0.05 was considered as significant. 
results
AMPK activation
To determine whether the two pharmacological substances 
AICAR and ZMP could exert physiological effects via activation 
Western blotting 
After boiling for five minutes, equal amounts of sample protein 
from the various fractions were separated on a 10% SDS-PAGE 
and transferred to ImmobilonTM-P membranes. Transfer and 
equal loading were confirmed using the reversible stain, Ponceau 
red. Non-specific binding sites were blocked with 5% fat-free 
milk powder in TRIS-buffered saline (TBS) for two hours at 
room temperature and then incubated with either the phospho-
Akt (Ser473), GLUT4 (H-61): sc-7938 or phospho-AMPK (Thr172) 
primary antibody [1:1000 dilution in TBS plus 0.1% Tween-20 
(TBST)] for 16 hours at 4°C. After washing with TBST, the 
membranes were treated for one hour with 1:4000 dilution of 
anti-rabbit Ig, horseradish peroxidase-linked whole antibody and 
the bands were visualised with the ECL method. 
Membrane fractionation for measurement of 
GLUT4 translocation
In order to determine GLUT4 translocation, cardiomyocytes 
were fractionated into a sarcolemmal membrane and a cytosolic 
compartment, essentially as described by Takeuchi et al.38 After 
stimulation with the various compounds, the cardiocytes were 
washed twice with ice-cold HEPES buffer without albumin and 
then sonicated on ice in TES buffer containing (in mM): Tris-
HCl 20, pH 7.5, EDTA 2, EGTA 0.5, sucrose 330 PMSF 1 and 
25 µg/ml leupeptin. The homogenate was centrifuged to remove 
particulate debris (1000 × g at 4°C for 10 min). 
The supernatant was further fractionated by ultracentrifuga-
tion for 90 min at 40 000 × g at 4°C (Beckman, Ti50). The 
supernatant obtained was considered to represent the cytosolic 
fraction. The pellet was suspended in the aforementioned buffer 
minus sucrose but containing 1% (vol/vol) Triton X-100 plus 1% 
SDS and rotated at 4°C for 30 min. Afterwards the suspension 
was ultracentrifuged at 40 000 × g for one hour at 4°C (Beckman, 
Ti50), and the supernatant used as the membrane fraction. 
Protein concentration was determined using the method of 
Bradford,37 samples were diluted in Laemmli sample buffer, boiled 
for 5 min and stored at –20°C. GLUT4 content and distribution 
were determined by Western blotting and suitable antibodies. 
Detection of GLUT4 exofacial loop
Approximately 100 000 cardiomyocytes per sample were used 
and washed once with PBS. After that, the cells were stained 
with 1 µg GLUT4 antibody coupled to Alexa Fluor 488 accord-
ing to the manufacturer’s instructions, and washed with PBS. 
A fixing step with 1 ml PBS containing 1% paraformaldehyde 
(PFA) for 15 min at room temperature followed. Samples were 
centrifuged at 4 × g for 5 min. Flow cytometric analysis was 
done with a FACSCalibur using Cellquest 3.3 software (Becton 
Dickinson, San Jose, California, USA). A forward-scatter against 
side-scatter plot was used to distinguish the cells from the debris, 
as described previously.39 The fluorescence signal of the labelled 
antibody bound to GLUT4 was detected in the FL-1 channel using 
logarithmic amplification. Positive cells were defined by a fixed 
gate and expressed as a percentage of the total cell population. 
Statistical analyses
Results are presented as mean ± SEM. The significance of the 
differences between groups was analysed with either a one-way 
Fig. 1. a: lysates of cardiomyocytes were prepared 
after stimulation for 30 min with either aiCar (1 mM) or 
ZMP (1 mM) as described in Methods; 50 µg of protein 
were loaded per lane, separated and, after Western 
blotting, probed with an antibody against the thr172-
phosphorylated form of aMPK. Cells made anoxic by 
bubbling nitrogen through the incubation medium were 
used as a positive control. after visualisation, blots were 
analysed with laser scanning densitometry. B: a repre-
sentative Western blot of phosphorylation of aMPK and 
aCC as substrate of aMPK to demonstrate activation. C: 
a Ponceau red-stained membrane to show equal loading 
of proteins. all values are expressed as mean ± sEM (n = 


























aicar – + – –
ZMP – – + –
anoxia – – – +
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Javaux et al.40 reported in 1995 that rabbit cardiomyocytes 
were unable to phosphorylate AICAR to ZMP. Because of the 
observed inability of AICAR to elicit glucose uptake in rat cardio- 
myocytes, we tested the ability of ZMP to affect glucose uptake. 
As seen in Fig. 2A, ZMP also significantly lowered basal glucose 
uptake levels 0.6 ± 0.22-fold (p < 0.05). To ascertain that this was 
not because AICAR or ZMP influenced cell viability, PI staining 
was performed at the end of the experimental protocol. Fig. 2B 
shows that cell viability was not affected by either substance.
GLUT4 translocation in cardiomyocytes
Because of the observed activation of AMPK by AICAR and 
ZMP, but not of glucose uptake, we assessed GLUT4 transloca-
tion under these conditions, fractionating the cells into cytosolic 
and membrane compartments, and then probing Western blots 
of the separated proteins with a specific GLUT4 antibody. As 
shown in Fig. 3A and B, a significant increase in GLUT4 could 
be seen between basal and stimulated cells in the membrane 
compartment (1.01 ± 0.01 arbitrary densitometry units vs insulin 
1.45 ± 0.2, AICAR 1.29 ± 0.10 and ZMP 1.56 ± 0.1). 
Determination of GLUT4 exofacial loop
In order to understand this discrepancy, we used an antibody 
directed against the exofacial loop of the GLUT4 protein, 
coupled to flow cytometry, to determine whether the protein was 
properly inserted into the membrane.41 As seen in Fig. 4, these 
of AMPK, the ability of these compounds to elicit phosphoryla-
tion of the kinase was determined. This was accomplished by 
measuring AMPK activation in terms of its phosphorylation on 
Thr172 via Western blotting and a specific antibody. In cardiomyo-
cytes treated with AICAR (1 mM for 30 min) and ZMP (1 mM 
for 30 min) it was found that both substances resulted in signifi-
cant phosphorylation of AMPK (Fig. 1A). Cells made anoxic by 
incubation in medium equilibrated with nitrogen were used as a 
positive control. To ascertain that the phosphorylated kinase was 
active, the phosphorylation of one of its downstream substrate 
proteins, acetyl-Co-A carboxylase (ACC) was determined on the 
same samples. Fig. 1B is a representative blot showing phospho-
rylation of AMPK and ACC after stimulation with both AICAR 
and ZMP, while Fig. 1C is a representative Ponceau red-stained 
membrane showing equal loading of protein.
Glucose uptake
Insulin (100 nM) increased glucose uptake significantly [7.0 ± 
0.71-fold (p < 0.05)] from basal levels in the cardiomyocytes, 
whereas AICAR (1 mM) diminished glucose uptake 0.6 ± 




























Control insulin aiCar ZMP
Fig. 2. a: glucose uptake of cardiomyocytes as meas-
ured by the accumulation of 2-deoxy-d-[3h] glucose over 
a 30-min incubation period after stimulation with 1 mM 
aiCar, 1 mM ZMP or 100 nM insulin. values are given as 
multi-fold stimulation over a baseline of 1. B: Pi staining 
of the cells was performed after treatment with insulin, 
aiCar and ZMP to demonstrate cell viability. all values 
are expressed as mean ± sEM (n = 8 individual prepara-
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Fig 3. a: sarcolemmal membrane distribution of glut4 
in basal, insulin- (100 nM), aiCar- (1 mM) and ZMP- (1 
mM) treated cardiomyocytes. glut4 was determined via 
Western blotting as described in Methods, on membrane 
fractions obtained by differential centrifugation and 
analysed with laser scanning densitometry. all values are 
expressed as mean ± sEM, (n = 5–10 individual prepara-
tions); **p < 0.01 vs basal. B: a representative Western 
blot to show content of glut4 in the membrane fraction 
of cardiomyocytes treated with aiCar (1 mM), ZMP (1 
mM) or insulin (100 nM).
46 kda
aiCar – – + –
ZMP – – – +
insulin – + – –
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results clearly demonstrate that AICAR stimulation of GLUT4 
translocation resulted in a protein not exposed on the outside of 
the cell. In addition, it was demonstrated that insulin treatment 
led to exposure of GLUT4 on the outside of the cardiomyocyte 
while AICAR treatment, in accordance with the diminished 
glucose uptake seen in Fig. 2A, attenuated the amount of protein 
that could be recognised by the antibody on the outer surface of 
the cell.
It is postulated that activation of PI-3-kinase or PKB/Akt 
plays an important role in the docking and fusion of GLUT4 
vesicles in insulin-stimulated glucose uptake.31,42 However, 
neither AICAR nor ZMP resulted in phosphorylation of PKB/
Akt (results not shown).
It has also been described that nitric oxide (NO) is important 
in AMPK-mediated glucose uptake and GLUT4 translocation.43 
Because myocytes produce much less NO than endothelial cells,44 
we tested the effects of an NO donor, sodium nitroprusside 
(SNP) in combination with AICAR on the exposure of GLUT4 
on the outside of cardiomyocytes, using the flow cytometric 
method. As shown in Fig. 4, SNP (100 µm) had no effect on the 
number of myocytes with the exofacial loop of GLUT4 exposed 
on the outside under control conditions. However, giving SNP 
together with AICAR led to enhanced exposure of GLUT4 on 
the outer surface of the cell. Contrary to expectation, this was not 
accompanied by enhanced glucose uptake (Fig. 5).
discussion
In this study we aimed to determine whether the pharmacological 
substance, AICAR, known to activate AMPK in skeletal muscle, 
also exerted similar effects on AMPK activation, glucose uptake 
and GLUT4 translocation in isolated, adult ventricular cardiac 
myocytes. Our results showed significantly increased AMPK 
phosphorylation of Thr172 in these cells after stimulation with 
AICAR (Fig. 1), corroborating findings in EDL skeletal muscle45 
and hypothalamic cells.46 However, Longnus et al.47 were unable 
to detect AMPK activation with AICAR in ventricular tissue. In 
view of the conclusion of Javaux et al.40 that in cardiomyocytes, 
AICAR is probably not phosphorylated to ZMP, we similarly 
tested the effect of ZMP and found increased phosphorylation of 
Thr172 also by this substance. Therefore, both AICAR and ZMP 
can increase phosphorylation of AMPK in isolated cardiomyo-
cytes.
An increase in AMPK activity leads to stimulation of glucose 
uptake in skeletal muscle.48,49 However, the significant AMPK 
phosphorylation noted in our study was not accompanied by 
a concomitant increase in cardiomyocyte glucose uptake (Fig. 
2A). On the contrary, there was a significant decrease in glucose 
uptake seen in both the AICAR- and ZMP-treated cells. This 
finding underscores the work by Jessen et al.50 which showed 
that basal glucose transport in AICAR-exposed animals was 
significantly lower in all muscles when compared to controls 
or exercised animals. Additionally, Al-Khalili et al.51 found that 
both chronic and short-term exposure to AICAR induced AMPK 
activation in primary human skeletal myocytes but no subsequent 
increase in glucose uptake. 
In contrast to the above, Russell et al.,14 using a slightly longer 
incubation time, showed that in heart papillary muscle, incuba-
tions with AICAR increased glucose uptake almost twofold 
and led to AMPK phosphorylation and GLUT4 translocation. 
Papillary muscle, of course, also contains endothelial and endo-
cardial cells.
Both insulin25,34 and AMPK52,54 stimulate glucose uptake 
by translocation of GLUT4 to the cell membrane. In view 
of the findings of Russell and co-workers,14 we quantified 
GLUT4 movement to the cell membrane after various stimuli. 
Fractionating cells into cytosol and sarcolemmal membranes, 
insulin, AICAR and ZMP treatment resulted in significantly 
more GLUT4 associated with the cell membrane (Fig. 3). 
Therefore neither AICAR nor ZMP could stimulate glucose 
uptake in isolated cardiomyocytes, whereas both substances 
were able to phosphorylate AMPK and elicit translocation of the 
GLUT4 transporter from the cytosol to the cell membrane. 
The concept that GLUT4 translocation and activation to 
transport glucose are two independent although interrelated 
occurrences that can be separated from one another has been put 
forward by Furtado et al.30 To substantiate this statement, it was 
demonstrated that intracellular delivery of PIP3 results in GLUT4 
Fig 5. Cardiomyocytes were stimulated as described in 
Fig. 4 where after they were allowed to accumulate 2-dg 
for a period of 30 min to determine glucose uptake. all 
values are expressed as mean ± sEM (n = 4 individual 
preparations); ***p < 0.0001 vs basal level, snP, aiCar 
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Basal snP insulin aiCar aiCar+snP
*
Fig 4. a. Cardiomyocytes were stimulated as described 
in Methods, with 1 mM aiCar, 100 nM insulin and 100 
µM snP. glut4 protein was visualised with alexa Fluor 
488 coupled to an antibody directed against the exofa-
cial loop of the protein. Positive cells were defined by a 
fixed gate and expressed as a percentage of the total cell 
population. all values are expressed as mean ± sEM (n = 
4 individual preparations); *p < 0.05 vs basal level.
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translocation and incorporation into the membrane, while no 
associated glucose uptake was detected.57 In addition, Funaki and 
co-workers created a cell-permeable phosphoinositide-binding 
peptide that could induce GLUT4 translocation to the plasma 
membrane in adipocytes without increasing glucose uptake.58 
We used an antibody directed against the exofacial loop of 
the GLUT4 protein, coupled to a flow cytometric method to 
determine the amount of GLUT4 exposed on the outer surface 
of cardiocytes after stimulation with either insulin or AICAR. 
This method clearly demonstrated enhanced exposure with insu-
lin but attenuated exposure with AICAR, similar to the profile 
of glucose uptake (Fig. 4). As this was in contrast to the results 
obtained by Davey et al.59 showing that ischaemia causes a 
marked translocation of GLUT 4 to the sarcolemmal membrane 
in whole beating hearts, we speculated on the possible role of 
NO in this process.
AMPK phosphorylates endothelial nitric oxide synthase 
(eNOS) on Ser1177.60 According to Li et al.,61 this activation modu-
lates glucose uptake and GLUT4 translocation in heart muscle. 
Although cardiomyocytes also contain NOS, isolated cardiocytes 
produce very little NO in comparison to cardiac endothelial 
cells.44 We therefore argued that the lack of NO formation and 
subsequent activation of the cGMP pathway may be responsi-
ble for the lack of glucose uptake in our cells. To test this, we 
supplemented the cells with NO with the addition of SNP. This 
demonstrated that indeed, simultaneous stimulation with SNP 
and AICAR resulted in significantly more GLUT4 protein now 
detectable with the antibody against the exofacial loop of the 
protein. However, contrary to our expectations, glucose uptake 
was not affected, underscoring the concept that there still has to 
be activation of the GLUT4 transporter after insertion into the 
membrane. These results then reinforce the finding of Li et al.61 
that more signals than NO in addition to AMPK are necessary to 
induce glucose uptake.
The results obtained in this study therefore argue that other, 
hitherto unidentified factors besides AMPK activation and 
GLUT4 translocation are necessary to induce glucose transport 
via this pathway. We furthermore concluded that these signals 
were not activated in the isolated cardiomyocytes via activation 
of AMPK, although they were active in beating cardiac muscle. 
Both AICAR and ZMP have proved valuable tools in this study. 
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